In September 2020, compelling research published in the peer-reviewed journal, Radiology concluded that the ProFound AI Risk model is effective in identifying women at a high likelihood of being diagnosed with breast cancer within two years of a negative screening mammogram and in possible need of supplemental screening. Likewise, with the addition of our recently introduced ProFound AI Risk offering, we believe we will move mammography from what is today an age-based screening paradigm to a risk-adjusted precision screening paradigm that is personalized for every woman.” “ProFound AI powered by Panorama offers unparalleled benefits to patients and radiologists alike, including a clinically proven improvement in sensitivity and specificity, which dramatically improves reading accuracy for mammograms and reduces the rate of false positives. “Our partnership with Solis underscores our ongoing commitment to improving women’s health and we are thrilled that even more women across the United States will benefit from our revolutionary technology that is helping to improve lives,” said Michael Klein, Chairman and CEO of iCAD. The ProFound AI platform powered by Panorama is compatible with all leading mammography systems and allows for seamless integration with major PACS for decision support capabilities across large networks. It assists radiologists by rapidly and accurately analyzing each individual DBT image to identify potentially malignant lesions. ProFound AI for DBT is a high-performing workflow solution trained with the latest in deep-learning AI capabilities. “ProFound AI will further enhance patient care and outcomes for the over one million women we serve while also supporting our continued growth and expansion.” “After a thorough evaluation of all available AI solutions, we have chosen iCAD’s ProFound AI platform as our sole breast health AI solution to integrate with our Hologic 3D mammography systems throughout our entire network,” said Grant Davies, President and Chief Executive Officer of Solis Mammography. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography, the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography’s nationwide network with its latest artificial intelligence (AI) breast health solutions, including ProFound AI® for DBT and ProFound AI Risk, the first and only clinical decision support tool to provide an accurate two-year breast cancer risk estimation based on a screening mammogram. Institutional Distribution IntelligenceĪgreement Positions Both Companies for Growth Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services’ Network.Non-Traditional Exchanges & New Markets.Directors’ and Officers’ Questionnaires.By learning and analyzing data on large drug-resistant cancers, AI can swiftly comprehend how cancer cells grow resistant to cancer treatments, which can assist improve medication development and drug use. In the fight against cancer medication resistance, artificial intelligence plays a key role. Different malignancies and medications may react in different ways, and data from high-throughput screening processes frequently demonstrate a link between cancer cell genetic diversity and therapeutic activity. AI can be used to forecast anticancer drug action or to aid in the discovery of anticancer drugs. Although deep learning's application in drug response prediction has just recently been examined, these types of models offer unique qualities that may make them more suitable for complicated tasks such as simulating drug reactions based on biological and chemical data. Machine learning provides a fantastic opportunity for us to evaluate chemical data and generate conclusions that can aid in drug development. The entire process of developing a new medicine generates a large amount of data. Machine learning and deep learning aids in anticancer drug development: Scientists are utilizing machine learning to construct and create reverse synthesis pathways for compounds, which is speeding up drug discovery.